Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice

Journal of Neuroscience

Volumn 28, Issue 18, 2008, Pages 4785-4794

  Shineman, Diana W ^a   Zhang, Bin ^a   Leight, Susan N ^a   Pratico, Domenico ^b   Lee, Virginia M Y ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Center for Neurodegenerative Disease Research   (United States)

Author keywords

Alzheimer's disease; Amyloid ; APP; Isoprostane; Lipid peroxidation; Thromboxane receptor

Indexed keywords

AMYLOID; ISOPROSTANE; MESSENGER RNA; TERUTROBAN; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; 3 ((6 AMINO (4 CHLOROBENZENESULFONYL) 2 METHYL 5,6,7,8 TETRAHYDRONAPHT) 1 YL)PROPIONIC ACID; 3-((6-AMINO-(4-CHLOROBENZENESULFONYL)-2-METHYL-5,6,7,8-TETRAHYDRONAPHT)-1-YL)PROPIONIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ISOPROSTANE DERIVATIVE; ISOPROSTANE F2ALPHA III; NAPHTHALENE DERIVATIVE; PEPTIDE FRAGMENT; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA STABILITY; WESTERN BLOTTING; ANIMAL; BRAIN; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; EMBRYO (ANATOMY); ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; METHODOLOGY; NERVE CELL; PATHOLOGY; PHYSIOLOGY; RADIOIMMUNOASSAY; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELLS, CULTURED; EMBRYO, MAMMALIAN; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; ISOPROSTANES; MICE; MICE, TRANSGENIC; NAPHTHALENES; NEURONS; PEPTIDE FRAGMENTS; PROPIONIC ACIDS; RADIOIMMUNOASSAY; RECEPTORS, THROMBOXANE;

EID: 44649118752     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0684-08.2008     Document Type: Article

References (66)

1. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA (2000) Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 101:2833-2840.
2. Banker G, Goslin K, eds (1998) Culturing nerve cells, pp 352-356. Cambridge, MA: MIT.
3. Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL (1993) Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome. Ann NY Acad Sci 695:91-102.
4. Blackman SC, Dawson G, Antonakis K, Le Breton GC (1998) The identification and characterization of oligodendrocyte thromboxane A2 receptors. J Biol Chem 273:475-483.
5. Borg C, Lim CT, Yeomans DC, Dieter JP, Komiotis D, Anderson EG, Le Breton GC (1994) Purification of rat brain, rabbit aorta, and human platelet thromboxane A2/prostaglandin H2 receptors by immunoaffinity chromatography employing anti-peptide and anti-receptor antibodies. J Biol Chem 269:6109-6116.
6. Brass LF, Shaller CC, Belmonte EJ (1987) Inositol 1,4,5-triphosphate- induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 79:1269-1275.
7. Brunetti L, Michelotto B, Orlando G, Recinella L, Di Nisio C, Ciabattoni G, Vacca M (2004) Aging increases amyloid beta-peptide-induced 8-isoprostaglandin F2alpha release from rat brain. Neurobiol Aging 25:125-129.
8. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Fournièr F, Thomas-Anterion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D (2006) Phenotype associated with APP duplication in five families. Brain 129:2966-2976.
9. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VMY, Doms RW (1997) Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3:1021-1023.
10. Cracowski JL, Stanke-Labesque F, Chavanon O, Corompt E, Veitl S, Blin D, Bessard G, Devillier P (2000) Thromboxane A(2) modulates cyclic AMP relaxation and production in human internal mammary artery. Eur J Pharmacol 387:295-302.
11. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, et al. (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27:394-401.
12. Gao H, Peng B, Welch WJ, Wilcox CS (1997) Central thromboxane receptors: mRNA expression and mediation of pressor responses. Am J Physiol Regul Integr Comp Physiol 272:R1493-R1500.
13. Gao Y, Tang S, Zhou S, Ware JA (2001) The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 296:426-433.
14. Giasson BI, Ischiropoulos H, Lee VMY, Trojanowski JQ (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32:1264-1275.
15. Gravina SA, Ho L, Eckman CB, Long KE, Otvos Jr L, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270:7013-7016.
16. Greco A, Minghetti L, Levi G (2000) Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 25:1357-1364.
17. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VMY (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57:721-729.
18. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52:3-13.
19. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349:617-620.
20. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
21. Hsu KS, Huang CC, Kan WM, Gean PW (1996) TXA2 agonists inhibit high-voltage-activated calcium channels in rat hippocampal CA1 neurons. Am J Physiol 271:C1269-C1277.
22. Huang JS, Ramamurthy SK, Lin X, Le Breton GC (2004) Cell signalling through thromboxane A2 receptors. Cell Signal 16:521-533.
23. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VMY (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762.
24. Jolly-Tornetta C, Wolf BA (2000) Regulation of amyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N). Biochemistry 39:7428-7435.
25. Kinsella BT, O'Mahony DJ, FitzGerald GA (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281:957-964.
26. Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, Lee VMY (2005) BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol 168:291-302.
27. Lee RK, Araki W, Wurtman RJ (1997) Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Proc Natl Acad Sci USA 94:5422-5426.
28. Lee RK, Knapp S, Wurtman RJ (1999) Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J Neurosci 19:940-947.
29. Lin X, Ramamurthy SK, Le Breton GC (2005) Thromboxane A receptor-mediated cell proliferation, survival and gene expression in oligodendrocytes. J Neurochem 93:257-268.
30. Ling Y, Morgan K, Kalsheker N (2003) Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol 35:1505-1535.
31. Liu F, Su Y, Li B, Ni B (2003) Regulation of amyloid precursor protein expression and secretion via activation of ERK1/2 by hepatocyte growth factor in HEK293 cells transfected with APP751. Exp Cell Res 287:387-396.
32. Mark RJ, Fuson KS, May PC (1999) Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage. J Neurochem 72:1146-1153.
33. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
34. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, Irizarry MC, Hyman BT (2007) Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res 1161:116-123.
35. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
36. Miggin SM, Kinsella BT (2002) Regulation of extracellular signal-regulated kinase cascades by alpha- and beta-isoforms of the human thromboxane A(2) receptor. Mol Pharmacol 61:817-831.
37. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44:410-413.
38. Montine TJ, Quinn JF, Montine KS, Kaye JA, Breitner JC (2005) Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis 8:359-367.
39. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87:9383-9387.
40. Morrow JD, Minton TA, Roberts LJ (1992) The F2-isoprostane, 8-epiprostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44:155-163.
41. Muja N, Blackman SC, Le Breton GC, Devries GH (2001) Identification and functional characterization of thromboxane A2 receptors in Schwann cells. J Neurochem 78:446-456.
42. Nishihara M, Yokotani K, Inoue S, Osumi Y (2000) U-46619, a selective thromboxane A2 mimetic, inhibits the release of endogenous noradrenaline from the rat hippocampus in vitro. Jpn J Pharmacol 82:226-231.
43. Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, Minamoto T, Ross J, Fuchs SY, Spiegelman VS (2006) CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature 441:898-901.
44. Pooler AM, Arjona AA, Lee RK, Wurtman RJ (2004) Prostaglandin E2 regulates amyloid precursor protein expression via the EP2 receptor in cultured rat microglia. Neurosci Lett 362:127-130.
45. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12:1777-1783.
46. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VMY (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21:4183-4187.
47. Pratico D, Clark CM, Liun F, Rokach J, Lee VMY, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59:972-976.
48. Prechtel AT, Chemnitz J, Schirmer S, Ehlers C, Langbein-Detsch I, Stulke J, Dabauvalle MC, Kehlenbach RH, Hauber J (2006) Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element. J Biol Chem 281:10912-10925.
49. Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, Mudge AW, Jazin E, Cairns NJ (2004) Amyloid precursor protein mRNA levels in Alzheimer's disease brain. Brain Res Mol Brain Res 122:1-9.
50. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 270:28257-28267.
51. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
52. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VMY (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network. J Biol Chem 275:2568-2575.
53. Slack BE, Nitsch RM, Livneh E, Kunz Jr GM, Eldar H, Wurtman RJ (1993) Regulation of amyloid precursor protein release by protein kinase C in Swiss 3T3 fibroblasts. Ann NY Acad Sci 695:128-131.
54. Tang M, Cyrus T, Yao Y, Vocun L, Pratico D (2005) Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 112:2867-2874.
55. Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, De Pooter T, van Duijn CM, De Deyn PP, Van Broeckhoven C (2006) Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 78:936-946.
56. Trojanowski JQ, Schuck T, Schmidt ML, Lee VMY (1989) Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 37:209-215.
57. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA (2001) Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54:565-568.
58. Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VMY (1996) Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 271:8966-8970.
59. Vetrivel KS, Thinakaran G (2005) Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66:S69-S73.
60. Westmark CJ, Malter JS (2001) Extracellular-regulated kinase controls beta-amyloid precursor protein mRNA decay. Brain Res Mol Brain Res 90:193-201.
61. Westmark CJ, Malter JS (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 5:e52.
62. Wilson CA, Doms RW, Lee VMY (1999) Intracellular APP processing and A beta production in Alzheimer disease. J Neuropathol Exp Neurol 58:787-794.
63. Wilson CA, Doms RW, Zheng H, Lee VMY (2002) Presenilins are not required for A beta 42 production in the early secretory pathway. Nat Neurosci 5:849-855.
64. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:278-282.
65. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VMY, Trojanowski JQ, Pratico D (2003) Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61:475-478.
66. Yarovinsky TO, Butler NS, Monick MM, Hunninghake GW (2006) Early exposure to IL-4 stabilizes IL-4 mRNA in CD4+ T cells via RNA-binding protein HuR. J Immunol 177:4426-4435.